Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug MK-1045 enters early human testing for lupus and RA

NCT ID NCT07363590

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This early study tests a new medicine, MK-1045, in about 21 people with lupus or rheumatoid arthritis. The main goal is to see if it is safe and tolerable at different dose levels. Participants receive the drug through an IV infusion, and researchers monitor for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MK-1045 (also called CN201), given as an IV infusion
What this could lead to
If this early study shows MK-1045 is safe, it could lead to a new treatment option for people with lupus or rheumatoid arthritis.
What could go wrong
This is a very small, early-phase trial focused on safety, not effectiveness. The drug may not work or could have side effects. It will take years before any treatment might be available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • ARENSIA Clinics ( Site 0902)

    RECRUITING

    Bucharest, Bucharest, 011658, Romania

  • ARENSIA Exploratory Medicine-Country Emergency Hospital- Arensia,Cluj-Napoca ( Site 0901)

    RECRUITING

    Cluj-Napoca, Cluj, 400006, Romania

  • Anima Diepenbeek ( Site 0601)

    RECRUITING

    Diepenbeek, Limburg, 3590, Belgium

  • Arensia Exploartory Medicine ( Site 1301)

    RECRUITING

    Tbilisi, 0112, Georgia

  • Chinese Academy of Medical Science Peking Union Medical College Hospital ( Site 1501)

    RECRUITING

    Beijing, Beijing Municipality, 100005, China

  • Chulalongkorn University ( Site 0501)

    RECRUITING

    Pathumwan, Bangkok, 10330, Thailand

  • Clinica de la Costa S.A.S. ( Site 0101)

    RECRUITING

    Barranquilla, Atlántico, 080020, Colombia

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1901)

    RECRUITING

    Roma, 00168, Italy

  • Fundacion Valle del Lili ( Site 0102)

    RECRUITING

    Cali, Valle del Cauca Department, 760032, Colombia

  • Gold Coast University Hospital ( Site 1601)

    RECRUITING

    Southport, Queensland, 4215, Australia

  • Istituto Clinico Humanitas- IRCCS ( Site 1902)

    RECRUITING

    Rozzano, Milano, 20089, Italy

  • Keio University Hospital ( Site 0302)

    RECRUITING

    Shinjyuku, Tokyo, 160-8582, Japan

  • Oncomédica S.A.S ( Site 0103)

    RECRUITING

    Montería, Departamento de Córdoba, 230002, Colombia

  • PMSI Republican Clinical Hospital "T.Mosneaga" ( Site 1001)

    RECRUITING

    Chisinau, 2025, Moldova

  • Ramathibodi Hospital ( Site 0503)

    RECRUITING

    Ratchathewi, Bangkok, 10400, Thailand

  • The First Affiliated Hospital of Henan University of Science &Technology ( Site 1502)

    RECRUITING

    Luoyang, Henan, 471003, China

  • The University of Tokyo Hospital ( Site 0301)

    RECRUITING

    Bunkyo, Tokyo, 113-8655, Japan

  • UZ Gent ( Site 0602)

    RECRUITING

    Ghent, Oost-Vlaanderen, 9000, Belgium

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1504)

    RECRUITING

    Wuhan, Hubei, 430058, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.